15.00 - 15.30
Keynote speech

Scotland:

• Nicola Rowan, National Coordinator for Viral Hepatitis, Scottish Government
• Tony Cassidy, Scottish Drug User Representative

France

• Prof Daniel Dhumeaux, University of Paris-Est
• Miguel Velazquez Gorsse, president ASUD

Germany

• Dr. Ingo Michels, Head of Unit, Office of the Federal Drug Commissioner
• Dirk Schäffer, European Network of People Who Use Drugs, Deutsche Aids Hilfe

17.00 - 18.30
What do we want for the future: Presenting the Manifesto / Berlin Declaration:

7 stakeholders for the 7 key messages for a better hepatitis C policy and practice:

1. Scale Up Harm Reduction Community Based Programmes - Maria Phelan, Harm Reduction International (HRI)
2. Access to HCV Testing, Treatment and Care Services - Prof. Mojca Maticic, Clinic for Infectious Diseases and Febrile Illnesses University Medical Centre Ljubljana
3. Access to Affordable HCV Treatments - Anya Sarang, Andrey Rylkov Foundation, Moscow
4. Decriminalisation of People Who Use Drugs - Christopher Hallam, International Drug Policy Consortium
5. Meaningful Involvement of High Risk Communities - Efi Kokkini, European Network of People Who Use Drugs
6. Improved HCV and Health Literacy - Magdalena Harris, PHD, Centre of Research on Drugs and Health Behaviour, London School of Hygiene and Tropical Medicine
7. Effective Targeted HCV Strategies and Action Plans - Achim Kautz, European Liver Patient Association (ELPA)  

09.00 - 10.30

Access to hepatitis C treatment in Europe and abroad - the politics on pricing

• Luis Mendao, European Aids Treatment Group: Access to Hepatitis C treatment in Europe and abroad - The question of pricing and the view of people living with Hepatitis C
• Chloe Forette, Medicine du Monde: Nobody left behind - Global overview of hepatitis C treatment access and people who use drugs
• Paata Sabelashvili, Georgian Harm Reduction Network
• Gaëlle Krikorian, Advisor on Intellectual Property and Access to Knowledge, Green Party in the EP Ricardo Bapista : Basic maths, logical conclusions
• Ricardo Baptista Leite, MP Portugal: Hepatitis C in Portugal: From Public Health to Policy

11.00 - 12.30

Parallel Session 1: HCV treatment and care - the way forward

• Amber Arain - Treatment efficiency and safety results of first generation DAA- based regimes
• Chis Ford - Integrated care for the treatment of Hepatitis C: Ways of improving access to treatment
• Magdalena Harris - ‘Treatment as prevention‘ for hepatitis C: What does this mean for people who inject drugs?

Parallel Session 2: HCV in migrants and MSM - challenges and responses

• Fred Bladou - SLAM - Drugs by injection in the gay community in a sexual context
• Mick Quinlan - Hepatitis C and MSM in Ireland – a need for awareness?
• Luis Mendao - HCV and HIV commu- nity testing and linkage to care for migrant

Parallel Session 3: HCV in prison settings

• Vic Arendt - High recurrence rate of Hepatitis c infec tion after treatment in prison
• Heino Stöver - Epidemiology and Prevention of HCV in Prisons
• Discussion: Recommendations regarding hepatitis C prevention, screening and treatment in prisons

Workshop W1 Demonstration of FibroScan® testing

• Dr. Elisabeth Avril, Assoc. Gaia, Paris

Workshop W2 How to create impact on policy making for HCV?

• Jose Queiroz, Apdes

Parallel Session 1: Hepatitis C testing and treatment barriers among active drug users

• Heike Zurhold - Hepatitis C testing and treatment barriers among active drug users in European cities
• Ruth Zimmermann - Hepatitis C testing and treatment barriers among active drug users in Germany – results from the DRUCK-study
• Marie Jauffret-Roustide - Rapid testing and access to HCV treat- ment among drug users – paradoxical perceptions of health professionals. Results of “ANRS-Cube” research

Parallel Session 2: Drug User Driven Session

• Miguel Velazquez Gorsse - ASUD’s experience: 20 years of peer-to- peer-work to become aware of Hep C
• Maria Teresa Ninni - HCV Peer Support: the alliance between practical experien ces and professional knowledge
• The Swedish Drug User Union: Liver or die! 

Parallel Session 3: Hep C policy between negligence and adaption: Ukraine, Russia and European Union

• Anya Sarang - Hepatitis C in Russia: an epidemic of negli gence
• Ludmila Maistat- Scaling up access to HCV treatment for PWID‘s in Ukraine
• Mojca Maticic - Strategies for treat- ment of hepatitis C in Europe: an overview

Parallel Session 4: Reach out to patient groups - what works and what not

• Marie Debrus - Experience from an Innovative community-based educational intervention among active injec- ting drug users
• Agnes van der Poel - Case finding and treatment of HCV in addiction car
• Alexander Würfel - Lasting improvement in the level of care for patients on substitution treatment with hepatitis C – experiences of AbbVie Germany

Workshop: W3

• HCV prevention skills Trainer: Danny Morris, Andrew Preston
• Topics to be addressed: strate- gies to reduce accidental sha- ring; the role of foil provision; increasing NPS coverage